The Peptides Influencers Are Promoting: What the Hype Gets Wrong and What Your Clinic Should Say

If you run a med spa, wellness clinic or telehealth practice, patients are already asking you about peptides they saw on a podcast or a fitness account. The pitch is consistent: faster recovery after training, healed tendons and joints, quicker wound repair, more energy, better performance. The names change but the formula does not — a catchy stack name, a before-and-after story, and a link to buy.

The honest position for a clinic is neither "no" nor "sure." It is knowing what each of these substances actually is, what the evidence supports, and where it sits legally today, so your answer is accurate and defensible.

What Is Being Promoted, and What the Claims Are

These are synthetic peptides, meaning short chains of amino acids made in a lab. Some peptides are legitimate, approved medicines: insulin and GLP-1 drugs are peptides. The problem is not the category. It is that these particular substances have not been shown in rigorous human trials to do what the marketing says.

• BPC-157 and TB-500 (the "Wolverine Stack"): marketed together for tendon, ligament and joint healing, post-workout recovery and wound repair. The name borrows from a comic-book character with an accelerated healing factor, which tells you what the marketing is promising.
• MOTS-c: promoted as a metabolic and "exercise mimetic" peptide for energy, fat loss and performance.
• CJC-1295 and ipamorelin: growth-hormone secretagogues sold as a combination for muscle, recovery, sleep and anti-aging.

What the Evidence Actually Shows

When FDA's advisory committee reviewed seven peptide families in July 2026, FDA staff recommended against adding any of them to the 503A Bulks List, citing minimal evidence of safety or effectiveness and, for some, no human effectiveness or toxicology data at all. The committee voted to recommend six of the seven anyway, but a committee recommendation is advisory, and FDA has not yet acted on it.

Much of what drives the online enthusiasm is animal data, small studies, case reports and testimonials. A rat tendon result is not a human outcome, and an influencer's personal experience is not evidence of safety. That gap matters most for the risks that only show up over years: tumor promotion, immune reactions and effects on reproduction.

Where Each One Stands Legally Right Now

The status differs by substance, and treating them as one bucket is the most common mistake.

• BPC-157 and TB-500: reviewed by FDA's Pharmacy Compounding Advisory Committee in July 2026, which voted favorably. They are not on the final 503A Bulks List, FDA has not acted on the recommendation, and compounding them is not currently lawful on that basis.
• MOTS-c: same posture as above: a favorable committee vote in July 2026, not yet on the final list.
• CJC-1295: remains on FDA's Category 2 list of bulk substances that may present significant safety risks. FDA's listing cites immunogenicity risk for certain routes, peptide-related impurities, serious adverse events including increased heart rate and systemic vasodilatory reaction, limited clinical data, and nonclinical findings that it may be protumorigenic in some tissues.
• Ipamorelin: also a Category 2 substance, flagged in September 2023. FDA cites immunogenicity risk from aggregation and impurities, unnatural amino acids that complicate characterization, and a published report of serious adverse events including death when it was given intravenously for gastric motility.

The "Research Use Only" Problem

Most of the product patients buy after seeing these promotions is sold online as "research use only" or "not for human consumption." That label describes what the seller will stand behind, not what the law permits a clinic to do with it. Research-grade material has no pharmacy compounding behind it, no verified sterility, potency or purity, and no clinical oversight of sourcing. A clinic cannot lawfully administer it to a patient, and a patient injecting it at home carries all of that risk alone.

This is why the answer to "can you get me BPC-157?" is rarely a simple one. A licensed 503A pharmacy compounding a lawful substance for a named patient on a valid prescription is a completely different thing from a vial ordered off the internet.

How a Clinic Should Respond When a Patient Asks

• Start with the goal, not the product: ask what the patient is trying to fix — a tendon, recovery, energy, body composition. There are often established, evidence-backed options for the actual goal.
• Be specific about status: explain that these are in different legal positions and that you will only prescribe what your medical director can defend today.
• Do not advertise what you cannot lawfully offer: marketing a substance that is not currently compoundable, or implying outcomes, creates exposure on its own, separate from the clinical question.
• Document the conversation: a recorded discussion of risks, the lack of human evidence and the alternatives protects the patient and the clinic.
• Offer what is available: FDA-approved peptide drugs and lawfully compoundable substances are legitimate options when clinically appropriate.

Where MedGrid Fits

Your medical director should know which bucket every peptide a patient might ask about falls into today and update that when FDA acts. MedGrid connects you with a director who reviews your peptide protocols on a real cadence, and routes prescriptions only to licensed 503A and 503B pharmacy partners checked against what they may lawfully compound — so the answer your front desk gives is the one your physician would sign. We have broken down the vote that started this, the Category 1 versus Category 2 distinction, and how to keep a peptide program running through FDA's review in separate pieces.

Frequently Asked Questions

• What is the "Wolverine Stack"?: A social-media nickname for BPC-157 and TB-500 used together, marketed for accelerated healing and recovery. It is a marketing term, not a clinical protocol.
• Are these peptides FDA-approved?: No. None of BPC-157, TB-500, MOTS-c, CJC-1295 or ipamorelin is an FDA-approved drug.
• Can a clinic prescribe them?: Not lawfully through 503A compounding for BPC-157, TB-500 or MOTS-c as of this writing, because they are not on the final Bulks List. CJC-1295 and ipamorelin remain Category 2. Confirm current status with your medical director.
• Why did the committee vote yes if the evidence is thin?: Advisory votes weigh access and clinical interest alongside evidence, and FDA staff recommended against all seven families. The vote is a recommendation FDA has not adopted.
• Is it safe for a patient to buy these online?: There is no way to verify what is in a research-use-only vial or whether it is sterile. Combined with limited human safety data, that is the central risk.

This article is general educational information, not medical or legal advice. The regulatory status of individual peptides is actively changing; confirm current status with your medical director and qualified counsel before offering or prescribing any peptide.